Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

481
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
481
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

577
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
577
Glaucoma: Overview01:25

Glaucoma: Overview

630
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
630
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

221
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
221
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

1.4K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.4K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

895
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
895

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electronic health records: managerial insights from an umbrella review.

BMC health services research·2026
Same author

Persistent choroidal folds in myelin oligodendrocyte glycoprotein antibody-associated disease.

Multiple sclerosis and related disorders·2026
Same author

Definitions of Fast Progression in Glaucoma Literature.

Ophthalmology. Glaucoma·2026
Same author

Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Impact of visit schedule on estimated success rates in glaucoma surgical studies.

The British journal of ophthalmology·2026
Same author

Case Report: Progressive visual decline after optic neuritis associated with microcystic macular oedema.

Frontiers in neurology·2026

Related Experiment Video

Updated: Jul 26, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.1K

How latanoprost changed glaucoma management.

Maria Francesca Cordeiro1,2,3, Stefano Gandolfi4, Konstantin Gugleta5

  • 1Imperial College Healthcare NHS Trust, Western Eye Hospital, London, UK.

Acta Ophthalmologica
|June 23, 2023
PubMed
Summary

Prostaglandin analogues (PGAs) are now the first-choice glaucoma treatment due to efficacy and once-daily dosing. This review examines their 25-year impact on clinical practice and outcomes.

Keywords:
Latanoprostglaucomamedical treatmentopen-angle glaucomaprogressionprostaglandin analogues

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K
Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.4K

Related Experiment Videos

Last Updated: Jul 26, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.1K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K
Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.4K

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Glaucoma is a leading cause of visual impairment and blindness globally.
  • Topical medical therapy is the primary treatment for many glaucoma patients.
  • Latanoprost marked a significant advancement with a novel mechanism of action.

Purpose of the Study:

  • To review the role of prostaglandin analogues (PGAs) in glaucoma treatment.
  • To assess the impact of PGAs over 25 years since Latanoprost's introduction.
  • To evaluate the influence of PGAs on clinical practice outcomes.

Main Methods:

  • Literature review of studies on prostaglandin analogues in glaucoma.
  • Analysis of clinical practice trends and outcomes.
  • Examination of efficacy, side effects, and dosing of PGAs.

Main Results:

  • PGAs have become the first-choice treatment for primary open-angle glaucoma.
  • Key advantages include efficacy, limited systemic side effects, and once-daily dosing.
  • Common adverse events are mild to moderate ocular/periocular, including hyperemia and pigmentation.

Conclusions:

  • PGAs have revolutionized glaucoma management over the past 25 years.
  • Their favorable profile supports their continued role as a first-line therapy.
  • Understanding adverse events is crucial for patient management.